Member Info for marve

flyingmachine had it confirmed that lions head global partners are working with divoc and dr kanav

i think the site is just a holding page for now until divoc have the necessary approvals

"(I hope I am not putting too many words in your mouth Safy, just seems that we are on the same wavelength here)"

and nothing else for that matter either i hope magsy lol

there, my effort to lighten the mood

re divoc, if it helps us get sales in india then great, otherwise could not care less

good post big bite

saint, that is the problem, positives when the board is +15% but negative when it is level or down

is that not the general reaction of inexperienced investors, who can change their view on a daily basis

some of you will take this as offensive, so be it

we might as well stop pumping oil from our wells and pack it in then ey croz

not much i can add without being rude and saying to some to grow a pair, its just the name of the game

what if india approval lands in the next week and a regular order of 5m tests from then is announced to go with it? hello £50m of monthly revenue - what would that do to the share price...

i appreciate a lot of people would like to hear regular updates and see the share price steadily ticking up, but i guess we are past that now really

we are past the speculation stage and into reality, although i dont want to go as far as say this has become a binary play

however i consider gdr to be of incredible value risk / reward

to put it another way, who would like 5/1 on leeds winning the championship when they are currently 4/7

Not sure where this discussion is going

@swerves come on now dont be here for the wind up lol

you know it was just an illustration of how potential is factored in to valuations in certain markets

jadon sancho is 20 years old, he has 30 career goals and 34 career assists in 2 and a half years in the bundesliga, he also has 11 england caps

why do borussia dortmund price him at £100m? potential, potential, potential

a ftse100 company like lionel messi is based on results

an aim company is generally based on potential

what more is there to be said

i agree once significant sales of AIHL and HCV start it will have massive impact here in the underlying core of the business

ive not looked into the specifics of what ncyt also have in their locker so i cant comment, apart from analysing their last few year end accounts etc

but yes if the other tests gdr have can make the company self sufficient on its own (which we believe they can), that is a big big thing

that would be the cherry on top of the icing if the hiv and hearing loss test did that anytime soon while covid is the big focus

ever since the beginning i always had at least a £150m market cap in mind once we were selling high numbers of the tests

yes with only 35m shares in issue it is a bit different to now with 52m, however £150m is about £3 for starters

now if we look at ncyt at £180m we would be roughly £3.50

however, i have not been over there to look at how ncyt could still be undervalued, or if they are not

i recall the question being about how much profit ncyt were really making, how many tests they could really supply per month, and obviously the quality and accuracy of their test

i think, since they first launched their test, are they not trying to refine it also, like so it does not have as many different parts to it, and is more like our bead - i find the chatter between DB and their guys interesting

i do believe we have the better product, maybe the bigger manufacturing capacity too, and as long as the big sales come, and we and nicely informed of the big fat profits on them, then there should be no problem with us achieving a higher market cap in time

naturally if in this period we can also prove our non covid tests can generate substantial sales, which would mean gdr is profitable even without covid, then this would also be an incredible boost, as i believe ncyt were not profit making pre covid

as i understand it avct has a few big name investors over there which were in from the lows, which might have helped bring along plenty more private investors who follow those people

gdr might not have had that type of attraction early, i for one did not expect avct to be where it is, but all the best to them

i think a lot of us hoped gdr would have moved quicker than we have, but ncyt is not a bad timeline to compare to i dont think, and we are literally smack in the middle of the period when ncyt announced big approvals and first large orders

it cant be taken as fact when comparing, but ncyt completed product around start of feb and had approvals and first big orders start of april (2 months later)

we completed product start of may and now, today, we are in the start of july (2 months later)

call it fag packet working, but we are in the window right now

the past is the past, we all hoped things would have moved quicker but in hindsight that was just over expectation from us lot, compounded with many other events we have not held a higher base, but it is what it is

lets all look forward now

punter, bench has a substantial investment here, but can we just move on from the w 1 l l y waving now please

nice to see Peel now on the bid and pushing against the ask

lets see if they take us out of their holding pattern pre news

and £2.50 probably pays for miss world to join us in the hot tub lol

1. great to see Technik posting in detail, his decades of experience in the diagnostic sector was very valuable early on in March and April and continues to be - lets be honest some of us probably were not aware of the actual different between diagnostics and pharmaceuticals a few months ago, so his level of knowledge here is unparalleled

2. top work as always flyingmachine

3. respect to those holders that come across glass half empty with their posts but have openly stated they are just pessimistic people in general

come on safy who is this poster you mention

looks like someone has reached the betting against the market section of the dummies guide to investing

wonder what new words will be learnt by next week

grimshady, genedrive sold its contract research and pharmacogenomics division in june 2018, cath booth as i understand it was part of this transaction and she moved to what is now called epistem, i expert her shares in genedrive will have transfered over as part of the transaction, which on her linkedin is stated as a management buyout, so all fits

and the weakness of liverpool this season is they have only got 86 points out of 93, i mean what about those extra 7 points they could have had, glaring weakness isnt it...

ffs i never read so much garbage about genedrives weakness in its test

if the test fails to generate substantial sales, it will not be because of the lack of accuracy